Hypertension and Atrial Fibrillation treated by Rivaroxaban for the Morning and Night with sYnergy with calcium antagonists
- Conditions
- on-valvular atrial fibrillation (newly diagnosed patientsor patients taking an oral anticoagulant drug, and their primary physicians consider that switching to rivaroxaban is appropriate)
- Registration Number
- JPRN-UMIN000015775
- Lead Sponsor
- Jichi Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Not provided
Patients who meet any of the following criteria are not included in the study subjects. (1) Patients with cerebral stroke or systemic embolism that has occurred within the last 6 months (2) Patients with myocardial infarction, unstable angina, or a peripheral artery disease that has developed within the last 6 months (3) Patients with acute-phase heart failure (4) Hypertensive patients with an office systolic blood pressure of >=140mmHg even after treatment with an antihypertensive drug (5) Patients with renal failure (creatinine clearance, less than 30 mL/min) (6) Patients requiring two or more antiplatelet agents (concomitant use) (7) Patients who is using an anticoagulant drug other than dabigatran and warfarin (8) Patients requiring administration of an HIV protease inhibitor (oral drug) (9) Patients requiring administration of an azole antifungal agent (oral, or injection (except fluconazole)) (10) Patients being treated for malignant tumors (11) Patients who have undergone a surgery within the last 6 months (12) Patients with a rheumatic disease (13) Contraindicated cases of the study drugs (14) Patients who are pregnant or breast-feeding (15) Other patients that an investigator finds inappropriate to be included in the study population
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method